drugset / Trial / NCT01244958

Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis

NCT01244958 ↗

Phase 3 Completed 156 enrolled Frank Behrens
RandomizedParallel-groupDouble-blindTreatment

Summary

Combination of rituximab (RTX) with several different chemotherapeutic regimes has proven synergistic effects in patients with either lymphoma or autoimmune diseases. First data of uncontrolled trials with the combination of RTX and leflunomide (LEF) are available.

Timeline

Start
2010-08
Primary completion
2015-02
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rituximab Monoclonal antibody 500 mg Intravenous
Comparator Rituximab Monoclonal antibody 1000 mg Intravenous

Indications